151 related articles for article (PubMed ID: 6370515)
1. Vitiligo.
Sharquie KE
Clin Exp Dermatol; 1984 Mar; 9(2):117-26. PubMed ID: 6370515
[No Abstract] [Full Text] [Related]
2. Vitiligo: current medical and scientific understanding.
Boissy RE; Nordlund JJ
G Ital Dermatol Venereol; 2011 Feb; 146(1):69-75. PubMed ID: 21317859
[TBL] [Abstract][Full Text] [Related]
3. Vitiligo: Pathogenesis, clinical variants and treatment approaches.
Iannella G; Greco A; Didona D; Didona B; Granata G; Manno A; Pasquariello B; Magliulo G
Autoimmun Rev; 2016 Apr; 15(4):335-43. PubMed ID: 26724277
[TBL] [Abstract][Full Text] [Related]
4. Neurogenic dysregulation, oxidative stress, autoimmunity, and melanocytorrhagy in vitiligo: can they be interconnected?
Namazi MR
Pigment Cell Res; 2007 Oct; 20(5):360-3. PubMed ID: 17850509
[TBL] [Abstract][Full Text] [Related]
5. The genetics of generalized vitiligo.
Spritz RA
Curr Dir Autoimmun; 2008; 10():244-57. PubMed ID: 18460890
[TBL] [Abstract][Full Text] [Related]
6. [Vitiligo].
Njoo MD; Westerhof W
Ned Tijdschr Geneeskd; 1997 Apr; 141(16):759-64. PubMed ID: 9213796
[TBL] [Abstract][Full Text] [Related]
7. Review of the etiopathomechanism of vitiligo: a convergence theory.
Le Poole IC; Das PK; van den Wijngaard RM; Bos JD; Westerhof W
Exp Dermatol; 1993 Aug; 2(4):145-53. PubMed ID: 8162332
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune melanocyte destruction in vitiligo.
van den Wijngaard R; Wankowicz-Kalinska A; Pals S; Weening J; Das P
Lab Invest; 2001 Aug; 81(8):1061-7. PubMed ID: 11502857
[No Abstract] [Full Text] [Related]
9. Immune mechanisms in vitiligo.
Bystryn JC
Immunol Ser; 1989; 46():447-73. PubMed ID: 2488866
[TBL] [Abstract][Full Text] [Related]
10. Vitiligo.
Kovacs SO
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):647-66; quiz 667-8. PubMed ID: 9591808
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo.
Uchi H; Stan R; Turk MJ; Engelhorn ME; Rizzuto GA; Goldberg SM; Wolchok JD; Houghton AN
Adv Immunol; 2006; 90():215-41. PubMed ID: 16730265
[TBL] [Abstract][Full Text] [Related]
12. Immunopathogenesis of vitiligo.
Sandoval-Cruz M; García-Carrasco M; Sánchez-Porras R; Mendoza-Pinto C; Jiménez-Hernández M; Munguía-Realpozo P; Ruiz-Argüelles A
Autoimmun Rev; 2011 Oct; 10(12):762-5. PubMed ID: 21334464
[TBL] [Abstract][Full Text] [Related]
13. Cytokines: the yin and yang of vitiligo pathogenesis.
Singh M; Kotnis A; Jadeja SD; Mondal A; Mansuri MS; Begum R
Expert Rev Clin Immunol; 2019 Feb; 15(2):177-188. PubMed ID: 30462555
[TBL] [Abstract][Full Text] [Related]
14. Do we have to pay more attention to vitiligo patients? Peculiar histopathological features of primary cutaneous melanoma preceded by vitiligo.
Onsun N; Büyükbabani N; Ummetoğlu O; Cebeci F
J Dermatol; 2009 Nov; 36(11):612-5. PubMed ID: 19878396
[TBL] [Abstract][Full Text] [Related]
15. [Autoantibodies in vitiligo. Clinical significance].
Morgan M; Castells A; Ramírez A
Med Cutan Ibero Lat Am; 1986; 14(2):139-42. PubMed ID: 3528710
[TBL] [Abstract][Full Text] [Related]
16. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo.
al Badri AM; Foulis AK; Todd PM; Gariouch JJ; Gudgeon JE; Stewart DG; Gracie JA; Goudie RB
J Pathol; 1993 Feb; 169(2):203-6. PubMed ID: 8095298
[TBL] [Abstract][Full Text] [Related]
17. Melanocyte destruction and repopulation in vitiligo.
Norris DA; Horikawa T; Morelli JG
Pigment Cell Res; 1994 Aug; 7(4):193-203. PubMed ID: 7855062
[No Abstract] [Full Text] [Related]
18. Vitiligo as a systemic disease.
Lotti T; D'Erme AM
Clin Dermatol; 2014; 32(3):430-4. PubMed ID: 24767192
[TBL] [Abstract][Full Text] [Related]
19. Vitiligo.
Dunn JF
Am Fam Physician; 1986 May; 33(5):137-43. PubMed ID: 3706094
[TBL] [Abstract][Full Text] [Related]
20. Vitiligo. Clinical picture and pathogenesis.
McBurney EI
Arch Intern Med; 1979 Nov; 139(11):1295-7. PubMed ID: 508039
[No Abstract] [Full Text] [Related]
[Next] [New Search]
